10-K: Chicago Atlantic BDC Reports Strong 2025 Growth Amidst Cannabis Policy Shifts

Chicago Atlantic BDC (LIEN) announced significant portfolio growth and a 250% increase in net investment income for 2025, driven by its focus on cannabis and middle-market lending.

Summary

• Chicago Atlantic BDC, Inc. (LIEN) is an externally managed, closed-end, non-diversified management investment company, regulated as a Business Development Company (BDC) and a Regulated Investment Company (RIC).
• The company's investment objective is to maximize risk-adjusted returns on equity for shareholders, primarily by investing in secured and unsecured debt, equity warrants, and direct equity in privately held businesses.
• The investment strategy focuses on highly complex and regulated industries, predominantly the cannabis ecosystem, alongside growth & technology, esoteric & asset-based lending, and liquidity solutions opportunities.
• On October 1, 2024, the company completed the Loan Portfolio Acquisition from Chicago Atlantic Loan Portfolio, LLC (CALP), acquiring a portfolio of loans with a fair value of $219,621,125 in exchange for 16,605,372 shares of common stock.
• The Adviser and Chicago Atlantic BDC Holdings, LLC consummated a joint venture on October 1, 2024, combining investment management businesses, leading to a new Investment Advisory Agreement.
• As of December 31, 2025, the investment portfolio had an aggregate fair value of approximately $333.3 million across 39 portfolio companies, up from $275.2 million across 28 companies in 2024.
• The portfolio composition as of December 31, 2025, was 87.8% first lien, senior secured loans ($292.7 million), 11.2% senior secured notes ($37.5 million), 0.4% second lien, senior secured loans ($1.4 million), and 0.6% equity securities (warrants and preferred stock).
• The cannabis industry represented 74.7% of the portfolio's fair value as of December 31, 2025, with other significant sectors including Finance and Insurance (7.7%) and Information (6.0%).
• Geographically, the portfolio was concentrated in the Midwest (41.7%), Northeast (20.2%), and West (19.6%) regions of the United States as of December 31, 2025.
• For the year ended December 31, 2025, total investment income was $54.3 million, a 150% increase from $21.6 million in 2024.
• Net investment income for 2025 was $33.07 million, a 250% increase from $9.45 million in 2024.
• Total operating expenses increased by 90.2% to $23.2 million in 2025 from $12.2 million in 2024.
• The net change in unrealized appreciation (depreciation) on investments was $0.21 million in 2025, compared to $0.25 million in 2024.
• As of December 31, 2025, the company had $25.0 million in outstanding borrowings and $75.0 million available under its Revolving Line of Credit, with an asset coverage ratio of 1314%.
• No loans were on non-accrual status as of December 31, 2025, and 98.3% of investments were rated Grade 2 (performing in-line with expectations).
• The Dividend Reinvestment Plan (DRIP) was terminated effective December 31, 2025; all future cash dividends will be paid in cash.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong performance, marked by substantial growth in investment income and a robust asset coverage ratio, despite the inherent risks of its specialized cannabis and middle-market lending focus.

Positives

• The average fair value of the investment portfolio grew by 183% from 2024 to 2025, reaching approximately $310.4 million, indicating significant expansion.
• Net investment income increased substantially by 250% to $33.07 million in 2025 from $9.45 million in 2024.
• Total investment income rose by 150% to $54.3 million in 2025 from $21.6 million in 2024.
• The company maintains a robust asset coverage ratio of 1314% as of December 31, 2025, significantly exceeding the 150% regulatory requirement for BDCs.
• No loans were on non-accrual status as of December 31, 2025 and 2024, reflecting strong portfolio credit quality.
• A high percentage (98.3%) of investments were rated Grade 2 (performing in-line with expectations) as of December 31, 2025.
• President Donald Trump signed an executive order in December 2025 to expedite the reclassification of cannabis from Schedule I to Schedule III, signaling a potentially favorable federal policy shift for the cannabis industry.
• The company has an active pipeline of approximately $732 million in potential investments, suggesting future growth opportunities.

Negatives

• Total operating expenses increased by 90.2% to $23.2 million in 2025, outpacing the growth in net investment income.
• The net change in unrealized appreciation (depreciation) on investments decreased to $0.21 million in 2025 from $0.25 million in 2024.
• The market price of common stock on March 18, 2026, was $9.90, representing a 25.6% discount to the NAV per share of $13.30 as of December 31, 2025.
• The Expense Limitation Agreement, which capped operating expenses, expired on September 30, 2025, and was not renewed, potentially leading to higher operating expenses in future periods.
• The Adviser and CALP, holding significant amounts of common stock, may sell or distribute these shares, which could adversely affect the market price of the common stock.

Risks

• Economic recessions or downturns may materially adversely affect business, financial condition, and results of operations, impairing portfolio companies' ability to repay debt or pay interest.
• Global economic, political, and market conditions, including ongoing conflicts (Russia-Ukraine, Middle East), could adversely affect business and portfolio companies.
• Cybersecurity risks and incidents may disrupt operations, compromise confidential information, and damage business relationships.
• The company has limited operating history and its Adviser has limited history managing BDCs and making credit investments in the nascent cannabis industry.
• The investment portfolio is recorded at fair value, which is inherently uncertain and may differ materially from realizable values.
• Dependence on the Adviser's key personnel; loss of key personnel could significantly harm the ability to achieve investment objectives.
• The business model relies on strong referral relationships; inability to maintain or develop these could adversely affect business.
• Failure to maintain BDC qualification would significantly reduce operating flexibility.
• Regulations governing BDC and RIC operations may affect the ability to raise capital or borrow, negatively impacting growth.
• Changes in laws or regulations, particularly those governing cannabis, may adversely affect business or require strategy alteration.
• Provisions of the Maryland General Corporation Law (MGCL) and of the company's charter and bylaws could deter takeover attempts and adversely impact the common stock price.
• Inability to invest a significant portion of IPO/follow-on proceeds on acceptable terms within an attractive timeframe.
• The need for additional capital to finance growth due to distributing at least 90% of taxable income as a RIC.
• Inability to pay distributions, or distributions may not grow or may be a return of capital. No limit on using offering proceeds to fund distributions.
• Corporate-level U.S. federal income tax if unable to maintain RIC qualification or satisfy the annual distribution requirement.
• Investments in portfolio companies may be risky, with potential for total or partial loss.
• Investments primarily in below-investment-grade securities ('junk') with speculative characteristics, illiquidity, and valuation difficulties.
• Potential investment in covenant-lite loans, increasing the risk of loss.
• Lack of liquidity in investments may adversely affect business.
• Shares of closed-end investment companies, including BDCs, may trade at a discount to NAV.
• The market price of common stock may fluctuate significantly.
• Cannabis is illegal under U.S. federal law; strict enforcement would likely prevent business plan execution.
• Loans to relatively new/small companies and cannabis companies involve significant risks.
• Investment opportunities limited by federal illegality of cannabis; changes in laws could adversely affect the ability to make investments.
• Strict enforcement of federal cannabis laws could result in portfolio companies' inability to execute business plans and loss of loans.
• The nascent status of the medical/recreational cannabis industry involves unique circumstances and there can be no assurance of continued existence or growth.
• Cannabis industry growth is subject to new and changing state/local laws and regulations.
• Portfolio companies may have difficulty borrowing from or accessing banks due to cannabis-related activities.
• Unfavorable publicity or negative consumer/investor perception for the company, portfolio companies, or the cannabis industry.
• Third-parties may perceive reputational risk from association with the company and elect not to do business.
• Portfolio companies subject to regulatory, legal, or reputational risk from potential misuse of products by customers.
• Lack of access to U.S. bankruptcy protections for cannabis portfolio companies.
• U.S. federal courts may refuse to enforce contracts pertaining to federally illegal business operations (cannabis).
• Sales of common stock after the Loan Portfolio Acquisition by CALP members could cause the market price to decline.
• Inability to realize anticipated benefits from the Loan Portfolio Acquisition, including cost savings, or longer integration time.
• The Incentive Fee on Capital Gains may be effectively greater than 20% due to cumulative calculation.
• The Board may change investment objective, policies, and strategies without stockholder approval, with adverse effects.
• Dependence on information systems; system failures could disrupt business.
• Emerging growth company status may make shares less attractive or hinder capital raising.
• Failure to maintain effective internal control over financial reporting could lead to inaccurate reports or fraud.
• Significant costs incurred as a publicly traded company.
• The base management fee may induce the Adviser to incur leverage.
• Conflicts of interest due to executive officers/directors serving other entities with similar mandates.
• The Adviser's liability is limited and indemnified, potentially leading to riskier behavior.
• The Adviser and its affiliates may receive fees for services to portfolio companies not shared with the company.
• Leverage magnifies the potential for loss.
• Existing/future credit facilities subject assets to security interests; default could lead to foreclosure.
• Difficulty obtaining indebtedness in current market conditions.
• OID and PIK interest expose the company to higher risks, including non-cash income for distributions.
• Investments in distressed/bankrupt companies carry significant risks.
• Portfolio companies may prepay loans, reducing yields.
• Risks from revolving credit facilities (unemployed funds, operational costs).
• No control over portfolio companies.
• Defaults by portfolio companies harm operating results.
• Second priority liens are subject to control by senior creditors.
• Unsecured debt investments lack adequate protection.
• Foreclosure on defaulted loans could result in losses.
• Collateral for loans is subject to extensive regulations, potentially limiting the realization of value.
• The market value of properties/equipment securing loans may decrease if not usable for cannabis operations post-foreclosure.
• Greater risk with investments acquired through assignments/participations.
• Foreign investment risks (exchange rates, political instability, taxes, less liquid markets).
• Non-diversified investment company status means concentration risk.
• Total return swap agreements expose the company to market, liquidity, and leverage risks.
• The ability to enter into derivatives and financial commitment transactions may be limited due to financial institutions' unwillingness to transact with cannabis-related companies.
• The health and wellness sector is highly regulated and competitive.
• Changes in laws, regulations, and guidelines that impact portfolio companies' businesses may cause adverse effects on operations.
• Portfolio companies operating in a highly regulated business will require significant resources.
• Differing regulatory environments may cause adverse effects on the company's or its portfolio companies' operations.
• Failure or significant delay in obtaining regulatory approvals could adversely affect the ability of portfolio companies to conduct their businesses.
• U.S. regulations and enforcement relating to hemp-derived CBD products are rapidly evolving.
• Marketing constraints under regulatory frameworks may limit a portfolio company's ability to compete for market share.
• Portfolio companies may become involved in regulatory or agency proceedings, investigations, and audits.
• Research in the United States, Canada, and internationally regarding the medical benefits, viability, safety, efficacy, and dosing of cannabis or isolated cannabinoids remains in relatively early stages.
• Portfolio companies may be subject to liability for risks against which they cannot insure or against which they may elect not to insure.
• The illicit supply of cannabis and cannabis-based products may reduce sales and impede a company's ability to succeed in such markets.
• If recreational or medical-use consumers elect to produce cannabis for their own purposes, it could reduce the addressable market for a portfolio company's products.
• The cannabis industry faces significant opposition, and any negative trends may adversely affect the business operations of portfolio companies.
• Competition from synthetic products may adversely affect the business, financial condition, or results of operations of a portfolio company.
• An initial surge in demand for cannabis may result in supply shortages in the short term, while in the longer term, supply of cannabis could exceed demand, which may cause a fluctuation in revenue.
• Consumer preferences may change, and the portfolio company may be unsuccessful in acquiring or retaining consumers and keeping pace with changing market developments.
• A portfolio company may have difficulty in forecasting sales and other business metrics.
• The technologies, process, and formulations a portfolio company uses may face competition or become obsolete.
• Many cannabis businesses are subject to significant environmental regulations and risks.
• Many cannabis businesses are dependent on key personnel with sufficient experience in the cannabis industry.
• There are a limited number of management teams in the cannabis industry that are familiar with U.S. securities laws.
• A portfolio company may be dependent on skilled labor and suppliers.
• Fraudulent or illegal activity by employees, contractors, and consultants may adversely affect portfolio companies' business, financial condition, or results of operations.
• A portfolio company may be reliant on key inputs and may not be able to realize its cannabis production or capacity targets.
• A portfolio company may be vulnerable to rising energy costs.

Future Outlook

The company anticipates continued strong demand for credit-based solutions in the cannabis industry, driven by companies preferring less dilutive growth capital and scarce equity capital. Overall capital markets activity is expected to increase as the industry awaits the completion of cannabis rescheduling. The lower middle-market is projected to continue offering premium yields and robust structural protections due to reduced competition and favorable deal terms.

Management Comments

• "We seek to capitalize on, among other things, what we believe to be nascent cannabis industry growth, and drive return on equity by generating current income from our debt investments and capital appreciation from our equity and equity-related investments."
• "We believe continued legalization of cannabis and the normalization of cannabis and its many uses therapeutic, recreational and general health and wellness, are creating an attractive opportunity to invest in related businesses."
• "We expect overall capital markets activity to pick up incrementally as the industry awaits rescheduling completion."
• "Regardless of the above timing, we continue to expect demand for credit-based solutions to increase, as companies continue to prefer less dilutive forms of growth capital and equity capital remains scarce."
• "We believe that the lower middle-market, and certain parts of the middle-market, will continue to offer better risk adjusted return potential, and stronger loan structures and covenants, in part due to the expertise required to underwrite companies in this part of the market, and in part due to reduced appetites for smaller deals among banks and large funds."

Industry Context

StockSavvy.ai notes that Chicago Atlantic BDC's strong focus on the cannabis industry positions it to benefit from ongoing legislative shifts, such as the potential reclassification of cannabis to Schedule III, which could ease tax burdens and potentially increase access to traditional financing, though it also risks increased competition. The continued fragmentation and regulatory complexity of the cannabis market, coupled with traditional banks' reluctance to lend, create a niche for specialty finance companies like Chicago Atlantic BDC. The company's expansion into growth & technology, esoteric & asset-based lending, and liquidity solutions in the lower middle-market aligns with a broader trend of private credit filling gaps left by traditional lenders and mega-funds, allowing for attractive pricing and stronger deal terms.

Comparison to Industry Standards

• The company's asset coverage ratio of 1314% as of December 31, 2025, significantly exceeds the 150% regulatory requirement for BDCs, indicating a very strong capital position compared to industry benchmarks.
• The concentration of 74.7% of the portfolio in the cannabis industry is a distinct characteristic compared to diversified BDCs, which typically have broader industry exposure.
• The high percentage of floating-rate debt investments (71.8%) with 63% at interest rate floors as of December 31, 2025, positions the company favorably in a rising interest rate environment compared to peers with higher fixed-rate exposure.

Management Changes

Corporate Governance

Legal Proceedings

• No material legal matters or litigation were pending as of December 31, 2025.

Related Party Transactions

• The Adviser receives a base management fee of 1.75% of the average value of the company's gross assets and a two-part incentive fee (20% of Pre-Incentive Fee Net Investment Income above a 1.75% hurdle, and 20% of cumulative realized capital gains net of losses/unrealized depreciation).
• The company reimburses the Adviser for administrative costs and expenses, including allocable portions of the Chief Compliance Officer (CCO) and Chief Financial Officer (CFO) compensation.
• Chicago Atlantic Admin, LLC, an affiliate, serves as a loan administrator and collateral agent for certain loans, collecting and disbursing payments. It allocated $852,297 in fees and $65,041 in PIK income to the company in 2025.
• The Adviser voluntarily and irrevocably waived $658,477 of general and administrative expenses in 2025, which are not subject to recoupment.
• As of December 31, 2025, $1,804,032 was due from affiliates (interest and principal payments receivable), which was collected in January 2026.
• The Adviser and its affiliates held approximately 14% of the company's voting stock as of December 31, 2025, giving them influence over corporate actions.
• The company co-invests with other investment vehicles managed by affiliates, in accordance with an exemptive order and allocation policies. As of December 31, 2025, $280,731,131 of the company's investments were co-investments.
• The Adviser, as the seed investor, provided initial funding by purchasing approximately 4.5 million shares in the IPO and has since transferred a substantial portion to its members. The Adviser does not expect to hold common stock indefinitely and may sell or distribute shares, potentially affecting the market price.

Stakeholder Impact

• Shareholders: Benefit from increased net investment income and quarterly cash dividends (post-DRIP termination). Face potential dilution if new shares are issued below NAV and risk of stock price volatility from large shareholder sales.
• Employees (Adviser's): Compensation structure (base salary, performance bonus, profit share in Adviser) aligns interests with company performance.
• Portfolio Companies: Benefit from access to capital in underserved markets, managerial assistance, and tailored financing solutions. Face risks from economic downturns, regulatory changes, and potential foreclosure.
• Creditors: Benefit from strong asset coverage (1314%) and secured positions on loans.
• Regulatory Bodies: The company's compliance with BDC and RIC regulations, and its code of ethics, demonstrates adherence to regulatory standards.

Next Steps

• The company will continue to invest in secured debt, unsecured debt, equity warrants, and direct equity investments in privately held businesses.
• The company will continue to focus on cannabis, growth & technology, esoteric & asset-based lending, and liquidity solutions sub-strategies.
• The company has an active pipeline of approximately $732 million in potential investments.
• The company will continue to monitor developments in economic, political, and market conditions.
• The company will continue to monitor its transactions and may make certain tax elections or dispose of securities to mitigate the effect of complex U.S. federal income tax provisions.
• The Board will continue to make quarterly determinations regarding distributions.
• The company will continue to evaluate the impact of adopting ASU No. 2024-03.
• The company will continue to monitor and manage cybersecurity risks.

Key Dates

Recommendation

The company demonstrates strong growth in net investment income and a robust asset coverage ratio, indicating solid operational performance and financial health. However, the significant discount of the stock price to NAV, coupled with the expiration of the expense limitation agreement and potential stock sales by the Adviser and CALP members, introduces uncertainty. The inherent risks of the cannabis industry and reliance on fair value estimates for illiquid investments also warrant a cautious approach. While the long-term outlook for its niche market is positive, these factors suggest a 'hold' position until there is more clarity on market pricing and the impact of increased operating expenses.

Keywords

Chicago Atlantic BDC, LIEN, BDC, Business Development Company, Cannabis, Specialty Finance, Direct Lending, Secured Debt, Private Credit, Investment Portfolio, SEC Filing, 10-K, Financial Results, Loan Portfolio Acquisition, Investment Management, Corporate Governance, Risk Management, Financial Reporting, Middle-Market Lending, Equity Warrants, Dividends, RIC, Regulated Investment Company, Sarbanes-Oxley, Cybersecurity, Interest Rates, Economic Conditions, Market Volatility, Compliance, Investment Strategy